Literature DB >> 2010628

Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area.

S K West1, P Rapoza, B Muñoz, S Katala, H R Taylor.   

Abstract

The epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area of Tanzania was investigated. Specimens for chlamydial isolation cultures and direct fluorescent antibody cytology were collected from 1085 children aged 1-7 years. Other data included examinations for signs of clinical trachoma and the collection of household data on risk factors. A total of 33% of children had a positive laboratory test for Chlamydia species. The most important factors for predicting chlamydial infection were the presence of a sibling with laboratory evidence of infection, increased number of flies around the house, a household that herded cattle, and practice of a local religion. Younger children and girls were at no increased risk for a positive laboratory test, although these subgroups have more clinical disease. The data are compatible with a model of less frequent episodes of reinfection as children become older.

Entities:  

Mesh:

Year:  1991        PMID: 2010628     DOI: 10.1093/infdis/163.4.752

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis.

Authors:  S J Rasmussen; L Eckmann; A J Quayle; L Shen; Y X Zhang; D J Anderson; J Fierer; R S Stephens; M F Kagnoff
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

2.  Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year.

Authors:  H Zhang; R P Kandel; H K Atakari; D Dean
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

3.  Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger.

Authors:  A Abdou; B Nassirou; B Kadri; F Moussa; B E Munoz; E Opong; S K West
Journal:  Br J Ophthalmol       Date:  2006-08-09       Impact factor: 4.638

4.  Community mass treatment with azithromycin for trachoma: Factors associated with change in participation of children from the first to the second round.

Authors:  Elizabeth N Ssemanda; Harran Mkocha; Joshua Levens; Beatriz Munoz; Sheila K West
Journal:  Clin Epidemiol Glob Health       Date:  2015-04

5.  Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation.

Authors:  D Zhang; X Yang; H Lu; G Zhong; R C Brunham
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

6.  Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.

Authors:  Z Dong-Ji; X Yang; C Shen; H Lu; A Murdin; R C Brunham
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 7.  Diagnosis and assessment of trachoma.

Authors:  Anthony W Solomon; Rosanna W Peeling; Allen Foster; David C W Mabey
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

9.  Chlamydia trachomatis-specific human CD8+ T cells show two patterns of antigen recognition.

Authors:  Malgosia K Matyszak; J S Hill Gaston
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.

Authors:  Ann-Margret Ervin; Harran Mkocha; Beatriz Munoz; Kurt Dreger; Laura Dize; Charlotte Gaydos; Thomas C Quinn; Sheila K West
Journal:  Ophthalmic Epidemiol       Date:  2016-11-07       Impact factor: 1.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.